Financial information
Introduction
For financial information earlier than the dates listed below, please go to www.sedar.com. Security holders may obtain a hard copy of our audited financial statements free of charge from the Chief Financial Officer of the issuer, by writing to him at: 9120 Leslie Street, Suite 205, Richmond Hill, ON, L4B 3J9, by telephone: 905-841-2300 x233, e-mail: ir@helixbiopharma.com, or fax: 905-841-2244.
YE 2022
Press release | Helix BioPharma Corp. announces fiscal 2022 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2022
AIF | Annual Information Form
Q3 2022
Press release | Helix Biopharma Corp. Announces Fiscal 2022 Third Quarter Results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2022
Press release | Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2022
Press release | Helix BioPharma Corp. announces fiscal first quarter 2022 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2021
Press release | Helix BioPharma Corp. announces fiscal 2021 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2021
AIF | Annual Information Form
Q3 2021
Press release | Helix Biopharma Corp. announces fiscal third quarter 2021 results
MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations
Q2 2021
Press release | Helix Biopharma Corp. announces fiscal second quarter 2021 results
MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations
Q1 2021
Press release | Helix BioPharma Corp. announces fiscal first quarter 2021 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2020
Press release | Helix BioPharma Corp. announces fiscal 2020 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2020
AIF | Annual Information Form
Q3 2020
Press release | Helix BioPharma Corp. announces fiscal third quarter 2020 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2020
Press release | Helix BioPharma Corp. announces fiscal second quarter 2020 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2020
Press release | Helix BioPharma Corp. announces fiscal first quarter 2020 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2019
Press release | Helix BioPharma Corp. announces fiscal 2019 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2019
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2019
Press release | Helix BioPharma Corp. announces fiscal third quarter 2019 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2019
Press release | Helix BioPharma Corp. announces fiscal second quarter 2019 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2019
Press release | Helix BioPharma Corp. announces fiscal first quarter 2019 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2018
Press release | Helix BioPharma Corp. announces fiscal 2018 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2018
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2018
Press release | Helix BioPharma Corp. announces fiscal third quarter 2018 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2018
Press release | Helix BioPharma Corp. announces fiscal first quarter 2018 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2017
Press release | Helix BioPharma Corp. announces fiscal 2017 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2017
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2017
Press release | Helix BioPharma Corp. announces fiscal third quarter 2017 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2017
Press release | Helix BioPharma Corp. announces fiscal second quarter 2017 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2017
Press release | Helix BioPharma Corp. announces fiscal first quarter 2017 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2016
Press release | Helix BioPharma Corp. announces fiscal 2016 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2016
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2016
Press release | Helix BioPharma Corp. announces fiscal third quarter 2016 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2016
Press release | Helix BioPharma Corp. announces fiscal second quarter 2016 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2016
Press release | Helix BioPharma Corp. announces fiscal first quarter 2016 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2015
Press release | Helix BioPharma Corp. announces fiscal 2015 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2015
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2015
Press release | Helix BioPharma Corp. announces fiscal third quarter 2015 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2015
Press release | Helix BioPharma Corp. announces fiscal second quarter 2015 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2015
Press release | Helix BioPharma Corp. announces fiscal first quarter 2015 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
YE 2014
Press release | Helix BioPharma Corp. announces fiscal 2014 year-end results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Annual report | Annual Report 2014
AIF | Annual Information Form
Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.
Q3 2014
Press release | Helix BioPharma Corp. announces fiscal third quarter 2014 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q2 2014
Press release | Helix BioPharma Corp. announces fiscal second quarter 2014 results
MD&A | Management’s discussion and analysis of financial condition and results of operations
Q1 2014
Press release | Helix BioPharma Corp. announces fiscal first quarter 2014 results
MD&A | Management’s discussion and analysis of financial condition and results of operations